Contact
Contraste élevé

Neuromuscular Research | Dirk Fischer

Ce contenu est disponible uniquement en anglais.

One of our main research interests is to identify objective clinical endpoints or surrogate imaging markers that are useful in evaluating disease progression in muscular dystrophies and related neuromuscular disorders. In close collaboration with the Department of Radiological Physics of the University Basel (Prof. Oliver Bieri) we are developing and evaluating novel quantitative MRI sequences to distinguish healthy from fatty degenerated muscle tissue. These methods are clearly superior to clinical scores when assessing the effect of novel interventions and treatments on disease progression.

Our second area of scientific interest includes clinical studies aimed to improve the energetic situation of muscle cells in patients with neuromuscular diseases. A positive effect on muscle metabolism of a treatment with metformin and L-arginine was assessed in a pilot study on 5 patients with Duchenne muscular dystrophy. Larger placebo controlled clinical trials using the same hypothesis of an amelioration of muscle metabolism were conducted on patients with Duchenne muscular dystrophy and Becker muscular dystrophy and were funded by Swiss National Science Foundation.

Research projects

Post-polio syndrome (PPS) is a condition that affects many polio patients years after recovery from an initial acute attack of the poliomyelitis virus. Most often patients start to experience slowly progressive muscle weakness and fatigue. We perform a randomised, placebo controlled trial to assess the influence of an oral treatment with L-citrulline on energy metabolism in muscles of post-polio patients and its effect on muscle function, endurance and quality of life. This study is sponsored by the Thomi-Hopf-Foundation.

ClinicalTrials.gov Identifier: NCT02801071

Recruitment of patients has been terminated.

The examination of the peripheral nervous system with ultrasonogaphy is an emerging non-invasive technique that became popular in the last few years. To distinguish a pathological swelling of the nerves from normal aspects a comparison with normal values from a group of healthy children is important. This investigator-initiated study aims to establish normal values for cross sectional areas of several upper and lower limb nerves and cervical roots in children and adolescents from 2 to 18 years.

ClinicalTrials.gov Identifier:NCT02570802

We are actually recruiting patients, please contact us.

At the university’s children hospital (UKBB), the phase III, double-blind, randomized, placebo-controlled trial SIDEROS (sponsored by Santhera®) aims to assess the efficacy of Raxone in slowing the rate of respiratory function decline in Duchenne muscular dystrophy (DMD) patients receiving concomitant glucocorticoids. Study participants will receive either Raxone (900 mg/day; given as 2 tablets 3 times a day with meals) or placebo for 78 weeks (18 months). The primary endpoint of the trial is change from baseline to week 78 in forced vital capacity % predicted (FVC%p). Patients completing the trial will be offered the opportunity to enroll in an open label extension study where all patients receive Raxone.

ClinicalTrials.gov Identifier:NCT02814019

We are recruiting patients, please contact us.

In this study the effect of Tamoxifen is evaluated in boys with Duchenne muscular dystrophy. Using the mouse DMD model encouraging results have been shown concerning the muscle function during a treatment with tamoxifen. Patients will be recruited internationals in 9 centers (7 countries), the trial will be coordinated by the UKBB (sponsored by EU, SNF, patient organizations: Duchenne UK, NL and Monaco).

We are not yet recruiting patients. Please contact us for more information. 

Approx. one billion people are suffering from migraine worldwide and yet, therapeutic options are still very limited. Research suggests that changes in energy metabolism could be part of migraine pathophysiology. Ketone bodies (KB) are endogenous alternative energy substrates. Our clinical trial assesses the efficacy and safety of KB supplements in 60-90 adult migraineurs (5-14 migraine days / months) at the University Hospital Basel. The total duration of the trial is approx. 6 months, consisting of 4 weeks baseline, 12 weeks intervention with KB powder or matched placebo and 8 weeks follow-up. The primary endpoint is the change in migraine days at the end of intervention compared to baseline. Additionally, changes in gene expression, fat-, protein- and glucose metabolism, inflammatory markers and quality of life will be examined.

We are currently recruiting. Please contact us for more information on the study.

Research group members

Ligne de conseil pour les urgences concernant les enfants et les jeunes

La Medgate Ligne pour enfants fournit des conseils médicaux rapides et simples lorsque votre enfant ne se sent pas bien. L'équipe médicale de notre partenaire Medgate se tient à votre disposition par téléphone 24 heures sur 24.

058 387 78 82
(facturation par la caisse de maladie)

Pour les urgences à l'étranger : Appelez le numéro d'urgence de votre caisse maladie. Vous trouverez ce numéro sur votre carte d'assurance maladie.

Plus d'informations : Sur la Page du service des urgences vous trouverez tout ce qu'il faut savoir sur le comportement à adopter en cas d'urgence, les maladies infantiles typiques et les délais d'attente.

Numéros d'urgence importants

144 Service ambulatoire
145 Tox Info Suisse (intoxications)
117 Police
118 Pompiers

UKBB

Hôpital pédiatrique universitaire des deux Bâle
Rue de l'Hôpital 33
4056 Bâle | CH

Contact

Sur quel sujet souhaitez-vous nous contacter ?
Pour les éloges ou les réprimandes, veuillez utiliser le Formulaire de feedback.

Raison de la prise de contact *

La prise de rendez-vous n'est pas possible via le formulaire de contact. Pour les prises de rendez-vous et les reports, veuillez vous adresser au centre de coordination de la polyclinique +41 61 704 12 20.

Nom du patient *
Prénom du/de la patient(e) *
Date de naissance du/de la patient(e) *
Nom *
Prénom *
Numéro de téléphone
Adresse électronique *
Votre demande *
Qui doit vous contacter ?
Comment souhaitent-ils être contactés ? *
Remarques *
Date d'annulation du rendez-vous
Prise de contact téléphonique pour un nouveau rendez-vous *
Raison du refus